Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

Abstract

This study defined the genetic epidemiology of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-TDV, and thereby enabled virus genotype-specific estimates of vaccine efficacy (VE). Envelope gene sequences (n = 661) from 11 DENV genotypes in 10 endemic countries provided a contemporaneous global snapshot of DENV population genetics and revealed high amino acid identity between the E genes of vaccine strains and wild-type viruses from trial participants, including at epitope sites targeted by virus neutralising human monoclonal antibodies. Post-hoc analysis of all CYD14/15 trial participants revealed a statistically significant genotype-level VE association within DENV-4, where efficacy was lowest against genotype I. In subgroup analysis of trial participants age 9-16 years, VE estimates appeared more balanced within each serotype, suggesting that genotype-level heterogeneity may be limited in older children. Post-licensure surveillance is needed to monitor vaccine performance against the backdrop of DENV sequence diversity and evolution.

DOI: 10.7554/eLife.24196

9 Figures and Tables

Cite this paper

@inproceedings{Rabaa2017GeneticEO, title={Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy}, author={Maia A Rabaa and Yves Girerd-Chambaz and Kien Duong Thi Hue and Trung Vu Tuan and Bridget A. Wills and Matthew I. Bonaparte and Diane van der Vliet and Edith Langevin and Margarita Cort{\'e}s and Betzana Zambrano and Corinne Dunod and Anh Wartel-Tram and Nicholas Jackson and Cameron P. Simmons}, booktitle={eLife}, year={2017} }